Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Nancy Shenoi, MD

Articles by Nancy Shenoi, MD

Trending on Psychiatric Times

Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia

FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia

Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression

Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders

Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder